腎臓移植の受け入れを助けるためのシプリズマブとウサギ抗胸腺細胞グロブリンの比較研究 (MODERNIZE1)
Phase 2b、無作為化、多施設共同、二重盲検、用量探索、活性薬対照試験:Siplizumab(TCD601)とウサギ抗胸腺細胞グロブリンの比較。対象は腎移植レシピエントで、導入療法を必要とし、タクロリムス、ミコフェノール酸およびコルチコステロイドによる標準的免疫抑制療法を受ける患者
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:
How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?
How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.
How does the body respond to siplizumab after dosing at each of the 2 dose levels?
How does siplizumab work in the body compared to rATG?
Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.
Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.
Participants will be monitored for 12 months after transplant surgery.
調査の概要
詳細な説明
Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.
Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:
- A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
- Premedication prior to study treatment infusions.
- Infection prophylaxis
This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.
Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.
Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.
Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90033
- 募集
- Keck Hospital of the University of Southern California
-
コンタクト:
- Melissa Ramos
- 電話番号:323-442-7983
- メール:Melissa.Ramos@med.usc.edu
-
Los Angeles、California、アメリカ、90095
- 募集
- University of California - Los Angeles, Connie Frank Kidney Transplant Center
-
コンタクト:
- Suphamai Bunnapradist, MD
- 電話番号:310-794-8516
- メール:bunnapradist@mednet.ucla.edu
-
Sacramento、California、アメリカ、95817
- 募集
- UC Davis Medical Center
-
コンタクト:
- Timothy Huynh, Clinical Research Coordinator
- 電話番号:916-703-4471
- メール:ttihuynh@health.ucdavis.edu
-
-
Florida
-
Tampa、Florida、アメリカ、33606
- 募集
- Tampa General Hospital
-
コンタクト:
- Jennifer Schmidt, BSN, RN
- 電話番号:813-844-7041
- メール:jenniferanilsen@tgh.org
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University Hospital
-
コンタクト:
- Emily Temponi, Study Coordinator
- 電話番号:404-712-1114
- メール:emily.k.temponi@emory.edu
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- 募集
- University of Kansas Hospital
-
コンタクト:
- Adam Schooley, MA, CCRP
- 電話番号:913-588-1699
- メール:aschooley@kumc.edu
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- 募集
- University of Kentucky Healthcare
-
コンタクト:
- Malay Shah, MD
- 電話番号:859-338-1615
- メール:malay.shah@uky.edu
-
-
Louisiana
-
Metairie、Louisiana、アメリカ、70006
- 募集
- Tulane Medical Center
-
コンタクト:
- Nicole Jackson
- 電話番号:504-988-5344
- メール:njackson3@tulane.edu
-
-
Massachusetts
-
Worcester、Massachusetts、アメリカ、01655
- 募集
- UMass Chan Medical Center
-
コンタクト:
- Anil Chandraker, MD
- 電話番号:508-334-7087
- メール:anil.chandraker4@umassmed.edu
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan - Michigan Medicine
-
コンタクト:
- Nerissa Reister, Clinical Research Coordinator
- 電話番号:734-763-5718
- メール:naflow@med.umich.edu
-
Detroit、Michigan、アメリカ、48202
- 募集
- Henry Ford Health
-
コンタクト:
- Matthew Callaghan
- 電話番号:313-916-4596
- メール:mcallag2@hfhs.org
-
-
New Jersey
-
Livingston、New Jersey、アメリカ、07039
- 募集
- Cooperman Barnabus Medical Center
-
コンタクト:
- Jayrol Mock, APN
- 電話番号:973-322-2339
- メール:Jayrol.Mock2@rwjbh.org
-
-
New York
-
New York、New York、アメリカ、10032
- 募集
- New York Presbyterian - Columbia University Irving Medical School
-
主任研究者:
- Lloyd Ratner, MD
-
コンタクト:
- Angela Sanchez, CRC
- 電話番号:212-305-3839
- メール:as5546@cumc.columbia.edu
-
コンタクト:
- Theresa Lukose, Research Director
- 電話番号:212-305-3839
- メール:tt2103@cumc.columbia.edu
-
New York、New York、アメリカ、10065
- 募集
- New York Presbyterian - Weill Cornell Medical Center
-
コンタクト:
- Jennifer Lee
- 電話番号:212-746-0192
- メール:jel9109@nyp.org
-
コンタクト:
- Meredith Aull
- 電話番号:212-746-5330
- メール:mea9008@med.cornell.edu
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke University Medical Center
-
コンタクト:
- Lynnette Moats
- 電話番号:919-949-6574
- メール:lynnette.moats@duke.edu
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- 募集
- University of Texas Southwestern Medical Center
-
コンタクト:
- David Wojciechowski, DO
- 電話番号:214-645-7846
- メール:David.Wojciechowski@UTSouthwestern.edu
-
-
Virginia
-
Falls Church、Virginia、アメリカ、22042
- 募集
- Inova Fairfax Hospital
-
コンタクト:
- Alma Khan, MSN, CCRC
- 電話番号:703-776-5912
- メール:Alma.Khan2@inova.org
-
Richmond、Virginia、アメリカ、23298
- 募集
- Virginia Commonwealth University Health
-
コンタクト:
- Meron Zeleke
- 電話番号:804-628-4969
- メール:Meron.Zeleke@vcuhealth.org
-
-
Washington
-
Seattle、Washington、アメリカ、98195
- 募集
- University of Washington Medical Center
-
コンタクト:
- Belinda Pan, Research Coordinator
- 電話番号:206-598-1562
- メール:bcpan@uw.edu
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitari Vall D'Hebron
-
コンタクト:
- Study Coordinator
- 電話番号:+34 932746000
- メール:assajos.nefrologia@vhir.org
-
Córdoba、スペイン、14004
- 募集
- Hospital Universitario Reina Sofía
-
コンタクト:
- Álvaro Torres, MD
- 電話番号:+34 957010440
- メール:nefro.hrs.sspa@juntadeandalucia.es
-
Málaga、スペイン、29010
- 募集
- Hospital Universitario Regional de Malaga
-
コンタクト:
- Study Coordinator
- 電話番号:+34 951291174
- メール:estudios.clinicos@ibima.eu
-
-
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、ブラジル、30150-320
- 募集
- Santa Casa Demisericordia de Belo Horizonte
-
コンタクト:
- Pedro Macedo de Souza
- 電話番号:+55 (31) 3238-8975
- メール:pmacedosouza@gmail.com
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、ブラジル、90035-903
- 募集
- Hospital de Clinicas de Porto Alegre
-
コンタクト:
- Research Coordinator
- 電話番号:+55 51 3359-6253
- メール:l-genetica@hcpa.edu.br
-
Porto Alegre、Rio Grande do Sul、ブラジル、90020-090
- 募集
- Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
-
コンタクト:
- Research Coordinator
- 電話番号:+55 51 3214-8640
- メール:pesquisa@santacasa.org.br
-
-
São Paulo
-
São José do Rio Preto、São Paulo、ブラジル、15090-000
- 募集
- Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
-
コンタクト:
- Research Coordinator
- 電話番号:+55 (17) 3201-5054
- メール:osvaldo.junior@centrodepesquisacip.com.br
-
São Paulo、São Paulo、ブラジル、04038-002
- 募集
- Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
-
コンタクト:
- Research Coordinator
- 電話番号:+55 (11) 5087-8110
- メール:hospital@hrim.com.br
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Recipients of a renal allograft from a non-HLA identical living or deceased donor.
- Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.
Exclusion Criteria:
- Transplant recipients seronegative for EBV.
- Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
- Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
- Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
- Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
- ABO-incompatible recipient.
- Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
- Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
- History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
- Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
- Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
- Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
- Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:低用量シプリズマブ
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
他の名前:
|
|
実験的:高用量シプリズマブ
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
他の名前:
|
|
アクティブコンパレータ:ウサギ抗胸腺細胞グロブリン
|
An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
時間枠:12 months
|
Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). |
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
時間枠:12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
時間枠:12 months
|
• Grade of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
時間枠:12 months
|
• Severity of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
時間枠:12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
時間枠:12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
時間枠:12 months
|
• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant. |
12 months
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
時間枠:12 weeks
|
Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
時間枠:12 weeks
|
Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
時間枠:12 months
|
Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant. |
12 months
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。